Opportunities for waste management from solar and…
Chris joined Sia in 2024 after the acquisition of Latham BioPharm Group, where he served as Director. He completed a Master’s in Chemical Engineering at Drexel University.
He has developed expertise in strategic transformation, financial modeling, product development, and market research, with experience in cell and gene therapies, small molecules, vaccines, medical devices, and digital health.
Over the course of his career, Chris has led initiatives to implement digital solutions for commercial process validation and quality management, including in previous roles at AstraZeneca and Merck & Co.
Today, Chris is based in Baltimore, focusing on strategic transformation, financial modeling, and market research in the life sciences and healthcare sectors.